FSRH CEU new product review: Drovelis® estetrol/drospirenone combined oral contraceptive (October 2022)
File size 248KB | Date: 27 October 2022
Date: 27 Oct 2022
Type: FSRH News and Information
Drovelis® is a new combined oral contraceptive containing estetrol and drospirenone. FSRH CEU reviews the evidence for its contraceptive effectiveness, safety, bleeding pattern and side effects and gives general guidance about medical eligibility and effective use.
Drovelis® is a new combined oral contraceptive containing the estrogen estetrol (E4) and drospirenone taken as a regimen of 24 active pills followed by 4 inactive pills.
Drovelis® E4/DRSP COC offers (user-dependent) contraceptive effectiveness comparable to that of other combined hormonal contraceptives. Safety profile, bleeding pattern and side effects appear similar to those with existing combined oral contraceptives. It is hoped that the ongoing International Active Surveillance Study which will report at 1 and 7.5 years will provide further evidence and may help to clarify whether the apparent lesser effect of E4-containing COC on e.g. haemostatic parameters impacts on associated health outcomes, particularly thrombotic risk.
FSRH CEU advises that UKMEC recommendations relating to medical eligibility for use of combined hormonal contraception apply also to Drovelis. DRSP is an aldosterone antagonist that could increase serum potassium; the manufacturer advises avoiding use by individuals with severe renal impairment or acute renal failure.